Relapsed Clinical Trials in Hangzhou, Zhejiang
30 recruitingHangzhou, Zhejiang, China
Showing 1–20 of 30 trials
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeOne Medicines780 enrolled277 locationsNCT05100862
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 1Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
Ascentage Pharma Group Inc.682 enrolled12 locationsNCT04501120
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Early Phase 1
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07376642
Recruiting
Phase 1
Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
Refractory/Relapsed B-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University48 enrolled1 locationNCT07398963
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 2Phase 3
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc501 enrolled57 locationsNCT04442022
Recruiting
Phase 3
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.324 enrolled19 locationsNCT06082102
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University72 enrolled1 locationNCT06621212
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Phase 1
The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.40 enrolled2 locationsNCT07073833
Recruiting
Phase 1
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
Hematologic MalignancyAML (Acute Myelogenous Leukemia)Refractory Acute Myeloid Leukemia+3 more
Hangzhou Weben Pharma Co., Ltd18 enrolled1 locationNCT07014449
Recruiting
Phase 1
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Advanced Solid TumorsRefractory LymphomaRelapsed Hematologic Malignancy
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.111 enrolled8 locationsNCT06615193
Recruiting
Phase 4
Clinical Study of OR for Second-line Treatment of Refractory MZL
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
Lixia Sheng39 enrolled3 locationsNCT06134284
Recruiting
Phase 1Phase 2
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd.83 enrolled5 locationsNCT06182696
Recruiting
Phase 2
Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML
Myeloid MalignancyRelapsed/Refractory Acute Myeloid Leukaemia
First Affiliated Hospital of Zhejiang University34 enrolled1 locationNCT06434662
Recruiting
Phase 1
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Advanced Solid TumorNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory
Tarapeutics Science Inc.26 enrolled1 locationNCT05650580
Recruiting
Not Applicable
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial
Relapsed Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University400 enrolled1 locationNCT05607329
Recruiting
Early Phase 1
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Acute Lymphoblastic Leukemia, in RelapseMultiple Myeloma in RelapseMultiple Myeloma, Refractory+3 more
Zhejiang University120 enrolled1 locationNCT04603872